Ramucirumab in advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: outcomes by prior transarterial chemoembolisation from two randomised, double-blind, placebo-controlled phase 3 studies (REACH-2 and REACH)
Meyer, T Finn, R Kudo, M Kang, Y Yen, C Galle, P Llovet, J Assenat, E Brandi, G Motomura, K
Meyer, T
Finn, R
Kudo, M
Kang, Y
Yen, C
Galle, P
Llovet, J
Assenat, E
Brandi, G
Motomura, K
Citations
Altmetric:
Abstract
Description
Date
2019
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Meyer T, Finn R, Kudo M, Kang Y, Yen C, Galle P, et al. Ramucirumab in advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: outcomes by prior transarterial chemoembolisation from two randomised, double-blind, placebo-controlled phase 3 studies (REACH-2 and REACH). Ann Oncol. 2019;30.